Spine Wave has begun a clinical study to determine the feasibility of implanting its NuCore injectable nucleus device using a proprietary percutaneous technique to treat degenerative disc disease.

NuCore material consists of rDNA-based protein polymer and a transient radiopacifier, which allows the material to be visualised intra-operatively during percutaneous injection.

The NuCore material will relieve pain, maintain disc height and restore biomechanical function in degenerative disc disease patients.

Dr Ulrich Berlemann of the Spine Center in Thun, Switzerland, said the initial results from an ongoing study involving the device have shown considerable reductions in pain scores within the three month post-operative evaluation.

Spine Wave chairman and CEO Mark LoGuidice said that the study will be an add-on to the previous clinical work, which demonstrated the device’s safety and that it could maintain disc height.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.